Biomedical research faces a persistent challenge: making sense of large-scale, high-dimensional data drawn from genetics, environment, imaging, and clinical records well enough to catch a disease's mechanism early, not merely name it after the fact. Doing this honestly requires knowing when a discovery is real, when a model's predictive performance can be trusted, and when a causal claim is solid enough for an institution to act on for the public's benefit. My past and future work confronts these challenges directly, aimed at narrowing the gap between lifespan and healthspan: the years a body survives versus the years it survives well.

I take that gap apart as one question, level by level, in a four-part essay series.

When Does a Discovery Reflect Real Signal, Not Dependency-Inflated Noise?

A persistent obstacle in large-scale hypothesis testing is that the theoretical null distribution routinely fails to describe the empirical distribution of test statistics once dependency enters high-dimensional biomedical data, which biases results toward false discoveries that look statistically clean.

Driven by that gap, I built an empirical null estimation method for zero-inflated discrete mixture distributions, an approach that can be read as an optimization problem minimizing the Kullback-Leibler divergence between the empirical and theoretical distributions, and extended the same protein-domain data into a rare-variant framework for tumor samples. Guided by the same concern in sparser data, I combined Bayesian estimation with empirical null modeling into a local false discovery rate method for protein domain hotspots, and, for grouped data of much higher dimension, into a correlation-adjusted simultaneous testing procedure, applied to methylation changes linked to type 2 diabetes where the dependency structure is otherwise invisible to a standard test. A related question, whether a risk difference is homogeneous across sparse count strata rather than an artifact of pooling them, needed a meta-analytic heterogeneity test built for count data rather than an adaptation of an existing one. Mentoring a graduate student on zero-inflated generalized Poisson models, characterizing the Fisher information matrix under missing data, extended this line of work into a setting especially relevant where excess zeros are common: rare disease occurrence, single-cell genomics, and microbiome studies.

The same testing machinery raises a second question I care about: can the tools built to catch false discoveries in genomics be turned toward auditing fairness in the predictive models now used in healthcare and elsewhere? Motivated by that question, I worked on Bayesian variable selection using knockoffs, a principled approach to feature selection with false discovery rate control in high-dimensional settings, as a first step toward that kind of audit.

Looking forward, I want to integrate Bayesian nonparametric methods into this line of work: Dirichlet process mixture models for empirical null estimation in heterogeneous datasets, Gaussian process approaches for functional and time-series data, and a sharper account of what a Bayesian nonparametric multiple testing procedure can guarantee. The empirical null problem's Kullback-Leibler framing, and the mutual-information reading of the prediction work described next, both point toward the same broader direction: statistical tests built on Wasserstein distances and other information-theoretic divergences that hold up when the underlying geometry of the data is not Euclidean. A recent collaboration using spectral entropy to quantify signal complexity and uncertainty in neuroimaging time series, in a regime where traditional statistical approaches struggle with a low signal-to-noise ratio, is the clearest evidence I have that this direction is not speculative.

What Does a Predictive-Performance Number Mean Once Feature Selection Is Part of the Pipeline?

A model's predictive-performance number means little once feature selection has already touched the same data used to evaluate it, and standard cross-validation treats that selection step as free, which it rarely is in high-dimensional settings.

Guided by that gap, I developed an exhaustive nested cross-validation approach that accounts for the feature selection process itself, systematically exploring all possible training-validation splits to give a more comprehensive assessment of predictive performance than traditional cross-validation, with theoretical guarantees derived from concentration inequalities in high-dimensional probability spaces that establish asymptotic control of Type I error under specific dependency structures. Read through an information-theoretic lens, this work can also be seen as optimizing the mutual information between the selected features and the response variable while controlling for overfitting. The same bias-variance tension shows up whenever features are highly correlated. Confronted by that, I worked on ridge penalization for high-dimensional testing in imaging genetics, tuning regularization parameters directly against the correlation, with results identifying genetic variants associated with brain imaging phenotypes.

It also shows up in data that is not a fixed set of variables at all. Classifying multivariate functional data, applied to fMRI recordings from patients with ADHD, required treating each patient's signal as a curve rather than a vector, and asking the same validation question in that different geometry: does a classifier trained on functional features generalize, or only fit the noise particular to one scan.

Building on this, I want to establish the asymptotic properties of exhaustive nested cross-validation in high-dimensional settings, quantify the uncertainty attached to a cross-validation-based test statistic, and develop adaptive cross-validation procedures that adjust automatically to a dataset's complexity.

What Has to Be True Before an Institution Acts on a Causal Claim?

A causal claim in biomedical research rarely gets to stay a scientific curiosity. Sooner or later it has to convince an institution, a regulator, a public health agency, a hospital, that the population it was drawn from and the study design behind it are strong enough to act on.

Motivated by that translation, I contributed to research mining and synthesizing causal relationships between diseases across the published literature to improve the use of polygenic risk scores, a step toward understanding complex disease networks and their genetic underpinnings, with implications for personalized medicine and preventive healthcare. The same question surfaces directly in public health work I have led or contributed to: as lead statistician for biosurveillance of SARS-CoV-2 in the Philippines through whole-genome sequencing, and for a proteomics-based discovery of lung cancer biomarkers and drug targets in the same country; in classifying congenital hypothyroidism at newborn screening, first with artificial neural networks and then with self-organizing maps, two different methods answering the same detection problem; and as project leader for a disability-registration framework tied to the Sustainable Development Goals. A study's adequacy is also a design question before it is a results question, which is what drove my work on power and sample size for experiments with high-frequency time-series responses. Each of these is a case of the same underlying question, asked under a different name and a different regulator: what has to be true about a causal claim, its population, and its study design before an institution is willing to act on it on the public's behalf.

The clearest future version of this question is bioequivalence and biosimilarity testing: establishing that a new therapeutic agent, biologic, chemical compound, or medical device performs comparably to an approved one, under the variability that shows up in a large patient population rather than a curated trial sample. I want to develop novel designs and statistical tests for bioequivalence studies, particularly for treatments targeting biomarkers identified through the high-dimensional methods described above, connecting the multiple-testing and cross-validation work directly to a decision a regulator has to make. The same causal-inference layer, extended with tools such as Mendelian randomization, also feeds into the biological-age work described below.

Can a Prediction of Disease Risk Carry Uncertainty a Clinician Can Act On?

Most predictive models return a single probability without a calibrated sense of how much to trust it, which is a poor basis for a decision that affects a patient's treatment.

Driven by that gap, I plan to develop a multiclass conformal prediction method for disease development and progression, giving a probabilistic assessment for an individual patient that comes with a distribution-free guarantee rather than an assumption borrowed from the model's training data. This is new work, not yet built, but it follows the same standard I hold the work above to: a claim about a patient's risk should state how confident it is, honestly.

Can Disease Progression Be Stratified Without Forcing It Into Fixed Cutoffs?

Disease progression rarely moves in a straight line, which makes it hard to say when a patient has crossed into a meaningfully different stage, or whether they will resolve on their own without ever reaching the event being studied at all.

Guided by that difficulty, I modeled clustered survival data with a cured fraction, letting a model represent that some patients in a cluster will never experience the event under study rather than forcing every survival curve toward the same eventual outcome. I extended a nonparametric version of the same clustering logic to customer survival data, a deliberately different domain that tested whether the same statistical structure, dependence within a cluster and heterogeneity in whether the event happens at all, holds outside biomedical data too.

Looking forward, I want to bring longitudinal data analysis into this same line of work: predictive models that account for fluctuations in environmental exposure and other dynamic factors over time, capturing the molecular and phenotypic variation that separates one disease subgroup, and one likely treatment response, from another, evaluated with the same nested cross-validation and false-discovery-rate control used throughout the work above so the stratification stays honest rather than overfit to a particular cohort.

Can Biological Age Close the Gap Between Lifespan and Healthspan?

All of this converges on the problem I consider the throughline of my research. Chronological age is a clock; biological age, estimated from methylation, imaging-derived brain connectivity, blood biomarkers, or telomere length, is an attempt to measure how much of the body's budget has been spent relative to that clock. I want to extend the toolkit built across the problems above, ridge-penalized regression, exhaustive nested cross-validation, false-discovery-rate control, and a causal-inference layer such as Mendelian randomization, into a full pipeline for testing whether a corrected biological-age gap predicts disease incidence and decline independently of chronological age, and whether narrowing that gap through intervention would translate into more years of healthy life rather than simply the same years of decline pushed later.

Rigor, Reproducibility, and the Responsible Use of Computational Tools

Statistical methods are powerful enough to be used well or used carelessly, and a false discovery in medical research can waste resources, sink a clinical trial, or license a harmful treatment. I hold my own work to a standard built around four commitments.

Transparency and reproducibility. Every result I produce has to be regenerable by someone who was not in the room when it was first produced, including a future version of myself. That means version-controlled code, documented pipelines, and papers that state plainly what a method can and cannot do rather than implying more than the evidence supports.

Open, reusable tools. Reproducibility is not only a property of one paper's code; it is a property of whether the next person working on a similar problem, at UK Biobank scale or otherwise, has to start from nothing. I want to build an open-source toolbox around the methods above, high-dimensional testing, nested cross-validation, and uncertainty quantification, so that the barrier to analyzing large-scale biomedical data is the size of the question, not the availability of tooling.

Clear-eyed use of computational tools, including AI. Increasingly, part of an analysis pipeline is written with the help of a large language model or a coding agent. I treat these tools as I would treat any other instrument in the lab: they can accelerate a literature search, translate a results table into readable prose, or draft code from a specification I have written myself, but they do not get to invent a claim, a citation, or a number. I am the author of every method, every commit, and every sentence that carries my name, and I have to be able to explain and defend each one without the tool in the room. Every reference is checked against its actual source before it enters a manuscript, never trusted from a model's memory.

Awareness of downstream stakes. Work on disease causality and genetics could eventually influence which patients receive which treatments, which is a responsibility that demands the highest standard of rigor and communicating findings with appropriate caution rather than overstatement, in publication and in mentorship alike.

Conclusion

My research program is organized around problems, not subfields: which discoveries are real, which performance estimates can be trusted, which causal claims are safe to act on, and how to give a patient calibrated, honest information about their own risk. Solving each has meant reaching into whichever tool the problem required, high-dimensional testing, cross-validation, functional data classification, survival analysis, causal inference, and, going forward, conformal prediction and longitudinal modeling. I am looking for a position where that combination, technical depth and a clear stake in the outcome, is what the work is judged on.